Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in older PWH. Topics include current data and recommendations on polypharmacy, drug–drug interactions, drug–disease state interactions, and cardiovascular risk considerations.
Jonathan Appelbaum, MD, FACP, AAHIVS
Jens D. Lundgren, MD, DMSc
Released: December 21, 2021

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:

  • DHHS, EACS, IAS, and WHO recommendations for first-line ART
  • Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
  • Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
  • Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART

Information on this Educational Activity

Faculty

Jonathan Appelbaum, MD, FACP, AAHIVS

Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida

Jonathan Appelbaum, MD, FACP, AAHIVS, has disclosed that he has received consulting fees from Merck and ViiV.
Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Jens D. Lundgren, MD, DMSc, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings